Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
Fecha de publicación
2015Título de revista
Arthritis and Rheumatology
Tipo de contenido
Publicación de congreso